Zanubrutinib joins the CLL treatment buffet

Lancet Oncol. 2022 Aug;23(8):965-967. doi: 10.1016/S1470-2045(22)00379-5. Epub 2022 Jul 7.

Authors

Pablo Mozas¹, Julio Delgado²

Affiliations

¹ Department of Haematology, Hospital Clinic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
² Department of Haematology, Hospital Clinic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; Universitat de Barcelona, Barcelona, Spain. Electronic address: jdelgado@clinic.cat.

PMID: 35810752
DOI: 10.1016/S1470-2045(22)00379-5

No abstract available

Publication types

Comment

MeSH terms

Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Piperidines / adverse effects
Protein Kinase Inhibitors / adverse effects
Pyrazoles / adverse effects
Pyrimidines / adverse effects

Substances

Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
zanubrutinib